September 20, 2021 -- PerkinElmer announced it has completed its $5.25 billion acquisition of life science antibody and reagent company BioLegend, a deal first announced in July.
The acquisition expands PerkinElmer's life science portfolio into cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.